PNPLA3 siRNA therapy (Eli Lilly and Company)

N/A

Report date: 2025/12/08 17:13:57

NME

Base Information

Drug NamePNPLA3 siRNA therapy (Eli Lilly and Company)

Drug Alias NameN/A

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of Action1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 inhibitors

Targets1-acylglycerol-3-phosphate O-acyltransferase PNPLA3

Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesEli Lilly And Company

China Registration ClassN/A

Develop Information

Active CompaniesEli Lilly And Company

Inactive CompaniesN/A

Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A